Monday, January 6, 2014
Eighteen U.S.-listed companies that completed IPOs in
2013 are down a median of 2% since their 180-day lockup periods expired. Taking
into account the strong performance of the biotech industry in 2013, the group
is down a median of 4% post-lockup relative to the BioCentury 100 index.
From the IPO date, the group is up 38%, or up 7%
compared with the BC100.